MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

BiOWiSH Technologies, Inc., a global provider of biotechnology solutions, has named Bill Diederich as Chief Executive Officer (CEO), effective immediately. Diederich, who has been with the company for ...

The research got the thrust after the Department of Biotechnology (DBT), Ministry of Science and Technology and Indian Space ...

The life sciences industry has a significant impact on the North Carolina economy. Using data from NCBiotech’s life sciences ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Monday, February 03, 2025. Let’s ...

引言近年来，癌症的治疗取得了一定的进展，但面对肿瘤细胞快速增殖和代谢紊乱的问题，传统的治疗手段仍显得力不从心。肿瘤细胞不仅依赖于异常的增殖信号，还通过改变自身的代谢途径来适应缺氧和营养匮乏的微环境，从而保证持续生长。这种现象被称为肿瘤代谢重编程，癌细胞通过增加葡萄糖的摄取和脂肪酸的氧化，不断为其快速 ...

MAIA首席执行官Vlad ...